A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT02795325 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperoxaluria Type 1

Interventions

DRUG: DCR-PH1
OTHER: Placebo

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company